Spruce Biosciences, Inc. (SPRB) stock
SPRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$43.31+0.42 (+0.98%)
Close on Nov 13, 2026Market cap $124.47MP/E –Yield –
Spruce Biosciences cash
Cash and short-term investments held at the end of each period.
Spruce Biosciences's cash was $87.70M at Sep 30, 2026. For fiscal 2025 it was $48.90M, up 26.0% from the year before. The highest annual figure on record is $157.37M in fiscal 2020.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $48.90M | +26.0% |
| FY2024 | Dec 31, 2024 | $38.80M | -59.7% |
| FY2023 | Dec 31, 2023 | $96.30M | +21.7% |
| FY2022 | Dec 31, 2022 | $79.10M | -11.3% |
| FY2021 | Dec 31, 2021 | $89.19M | -43.3% |
| FY2020 | Dec 31, 2020 | $157.37M | +3910.3% |
| FY2019 | Dec 31, 2019 | $3.92M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $87.70M | +719.6% |
| Q2 FY2026 | Jun 30, 2026 | $96.30M | +487.2% |
| Q1 FY2026 | Mar 31, 2026 | $54.10M | +111.3% |
| Q4 FY2025 | Dec 31, 2025 | $48.90M | +26.0% |
| Q3 FY2025 | Sep 30, 2025 | $10.70M | -82.2% |
| Q2 FY2025 | Jun 30, 2025 | $16.40M | -76.5% |
| Q1 FY2025 | Mar 31, 2025 | $25.60M | -68.5% |
| Q4 FY2024 | Dec 31, 2024 | $38.80M | -59.7% |
| Q3 FY2024 | Sep 30, 2024 | $60.10M | -44.4% |
| Q2 FY2024 | Jun 30, 2024 | $69.70M | -42.2% |
| Q1 FY2024 | Mar 31, 2024 | $81.20M | -31.5% |
| Q4 FY2023 | Dec 31, 2023 | $96.30M | +21.7% |
| Q3 FY2023 | Sep 30, 2023 | $108.00M | +19.5% |
| Q2 FY2023 | Jun 30, 2023 | $120.50M | +29.2% |
| Q1 FY2023 | Mar 31, 2023 | $118.60M | +29.8% |
| Q4 FY2022 | Dec 31, 2022 | $79.10M | -11.3% |
| Q3 FY2022 | Sep 30, 2022 | $90.40M | -2.1% |
| Q2 FY2022 | Jun 30, 2022 | $93.30M | -14.6% |
| Q1 FY2022 | Mar 31, 2022 | $91.35M | -38.5% |
| Q4 FY2021 | Dec 31, 2021 | $89.19M | -43.3% |
| Q3 FY2021 | Sep 30, 2021 | $92.32M | +27.9% |
| Q2 FY2021 | Jun 30, 2021 | $109.22M | +198.4% |
| Q1 FY2021 | Mar 31, 2021 | $148.63M | +258.9% |
| Q4 FY2020 | Dec 31, 2020 | $157.37M | +3910.3% |
| Q3 FY2020 | Sep 30, 2020 | $72.16M | +1393.3% |
| Q2 FY2020 | Jun 30, 2020 | $36.60M | – |
| Q1 FY2020 | Mar 31, 2020 | $41.41M | – |
| Q4 FY2019 | Dec 31, 2019 | $3.92M | – |
| Q3 FY2019 | Sep 30, 2019 | $4.83M | – |
See a number that looks wrong?